TSW
TSHA icon

Thompson Siegel & Walmsley’s Taysha Gene Therapies TSHA Stock Holding History

Thompson Siegel & Walmsley’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-56,100
Closed -$108K – 575
2022
Q3 		$108K Hold
56,100
– – ﹤0.01% 387
2022
Q2 		$209K Buy
56,100
+14,000
+33% +$55.5K ﹤0.01% 341
2022
Q1 		$274K Buy
+42,100
New +$315K ﹤0.01% 348

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Thompson Siegel & Walmsley's TSHA Position: Q4 2022 in Review

Thompson Siegel & Walmsley sold out of Taysha Gene Therapies (TSHA) in Q4 2022, closing a stake of 56,100 shares — an estimated $108K sold.

Thompson Siegel & Walmsley first reported a position in TSHA in Q1 2022 and held it in 3 quarters. The position peaked at $274K in Q1 2022. 52 funds tracked by Wall St. Rank hold TSHA as of Q4 2022.

  • Thompson Siegel & Walmsley reported no remaining Taysha Gene Therapies position as of Q4 2022 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 56,100 Taysha Gene Therapies shares in Q4 2022, an estimated $108K.
  • Thompson Siegel & Walmsley first reported a position in Taysha Gene Therapies in Q1 2022 and held it in 3 quarters.
  • Thompson Siegel & Walmsley's Taysha Gene Therapies position peaked at $274K in Q1 2022.
  • 52 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2022.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2022, filed 10 Feb 2023.